NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 75.5% and is now trading at $21.11. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.92 million. Cytokinetics had a negative net margin of 592.61% and a negative return on equity of 10,351.99%. View Cytokinetics' earnings history.

7 analysts have issued 12 month price objectives for Cytokinetics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Cytokinetics' stock price to reach $26.43 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price. View analysts' price targets for Cytokinetics.

News stories about CYTK stock have been trending somewhat negative on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -1.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCytokinetics.

Cytokinetics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 7,800,000 shares, a drop of 8.6% from the April 30th total of 8,530,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is currently 7.7 days. Approximately 14.4% of the company's stock are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Reata Pharmaceuticals (RETA), Myokardia (MYOK), Emergent Biosolutions (EBS), Forty Seven (FTSV), PPD (SDGR), Global Blood Therapeutics (GBT), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Biohaven Pharmaceutical (BHVN) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.35%), Wasatch Advisors Inc. (5.05%), State Street Corp (4.52%), Foresite Capital Management IV LLC (3.66%), Two Sigma Advisers LP (1.13%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Federated Hermes Inc., Two Sigma Investments LP, Pinnacle Associates Ltd., UBS Group AG, Arizona State Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Burrage Capital Management LLC, Atom Investors LP, JPMorgan Chase & Co., BNP Paribas Arbitrage SA, Two Sigma Advisers LP, State Street Corp, and Assenagon Asset Management S.A.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $21.11.

Cytokinetics has a market capitalization of $1.26 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]